Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients

NCT04321343 is registered in ClinicalTrials.gov with Poxel SA as lead sponsor.

NCT NCT04321343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04321343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
Lead sponsor
Poxel SA
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2020
Completion date
June 20, 2022
Enrollment
117 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis